During the COVID-19 pandemic, the problem of the population’s adherence to vaccination has become significantly aggravated around the world. This study is aimed at evaluating healthcare workers’ (HCWs) acceptance of COVID-19 vaccination in Russia. A cross-sectional multicenter study was carried out by interviewing HCWs in Russia using an electronic questionnaire and snowball sampling. The analysis included 85,216 questionnaires from 81 out of 85 regions of Russia. Statistical analysis was performed using SPSS v.22. The results indicated that 35.0% (CI 95%, 34.7–35.3) of HCWs were ready to get COVID-19 vaccination. The acceptance level was 42.4% (41.8–42.9) for all physicians and 31.3% (30.9–31.6) for nursing staff. A total of 29.4% (29.1–29.7) of HCWs were willing to recommend COVID-19 vaccination to patients: 38.5% (38.0–39.1) of physicians, and 24.7% (24.4–25.1) of nursing staff. Acceptance of COVID-19 vaccination is higher among HCWs dealing with infectious diseases and involved in vaccination. The low acceptance of HCWs toward vaccination against COVID-19 can be explained by the low level of awareness of HCWs in these issues. Additional educational programs are needed for HCWs, both for physicians and nurses, using all possible forms and methods of education.
Studies carried out in Moscow residents have revealed that the prevalence of chronic toxoplasmosis is very close to those in countries of Eastern and Central Europe. Our findings also demonstrated a statistically significant relationship between the rate of traffic accidents and the seroprevalence of chronic toxoplasmosis in drivers who were held responsible for accidents. The latter was 2.37 times higher in drivers who were involved in road accidents compared with control groups. These results suggest that the consequences of chronic toxoplasmosis (particularly a slower reaction time and decreased concentration) might contribute to the peculiarities of the epidemiology of road traffic accidents in the Russian Federation and might interfere with the successful implementation of the Federal Programme named “Increase road traffic safety”. Suggestions for how to address overcome this problem are discussed in this paper.
Introduction. The association between schizophrenia and toxoplasmosis has been demonstrated in a number of studies: the prevalence of schizophrenia is significantly higher in toxoplasmosis positive subjects than in those with T.gondii negative status. However, the clinical significance of this association remains poorly understood. Objectives. To identify clinical phenomena that are typical for toxoplasmosis-associated (T.gondii seropositive) schizophrenia compared to Toxoplasma-seronegative schizophrenia. Methods. A retrospective database analysis of serum samples from 105 inpatients with schizophrenia (ICD-10 code: F20; including 55 male patients; mean age of 27.4 ± 6.4 years) was carried out. The clinical examination involved a structured interview including ICD-10 and E. Bleuler's criteria for schizophrenia and psychometric tests (Positive and Negative Scales of PANSS). Serum antibodies (IgG) to T.gondii were identified using ELISA. The statistical significance of any differences were evaluated using the non-parametric Mann-Whitney (U) and χ 2 tests. Results. The proportion of seropositive patients in the sample was 16.2%. Comparing schizophrenia patients, who were seropositive or seronegative for toxoplasmosis, there were no statistically significant differences for the mean total PANSS score, mean PANSS-P, PANSS-N or PANSS-G scores. For the majority of PANSS items, differences were also statistically insignificant, except for G5 and G6-mannerism and posturing. Seropositive patients had a higher score for this item than seronegative patients: 3.5 versus 2.1 points (U=389.5; р=0.001). Depression, on the contrary, was less pronounced in seropositive than seronegative patients: 1.4 versus 2.4 points (U=509.5; р=0.023). In addition, in seropositive patients, the frequency of symptoms such as mutism according to ICD-10 criteria for schizophrenia Шизофрения и токсоплазмоз: ассоциация с кататоническими симптомами
Relevance. In a pandemic, studies on the duration of immunity in those who have recovered from COVID-19 and the formation of resistance to a new coronavirus infection are of particular importance.Target. To study the retention time of IgG in the blood serum of employees of a medical institution who recovered from a new coronavirus infection COVID-19.Materials and methods. The assessment of the timing of the formation of IgG was first carried out 3 weeks after the illness in employees of The National Medical Research Center for Otorhinolaryngology from April 2020 to December 2020. Further, the intervals for blood sampling to study the dynamics of antibodies to coronavirus infection were 3–4 weeks (9 blood samples for each ). Antibodies were examined by ELISA; immunological method for determining IgG (test system – "Vector Best", semi-quantitative analysis). Statistical processing of the study results was carried out using the SPSS-22 statistical software package and the OpenEpiver statistical calculator. 3.Results and discussion. The proportion of employees of a medical institution who recovered from COVID-19 was 39%, among them persons aged 36 to 55 years prevailed. It was found that class G immunoglobulins persist from seven months or more in 56.3% of those participating in the observation (the positivity coefficient is much higher than 1.2), in about 12.7% of those who had been ill, IgG in the blood serum persisted for about six months, in 11, 3% about three months. There were no statistically significant differences in the duration of immunity between men and women.Conclusion. A statistically significant direct relationship was found between age and the duration of immunity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.